Cocrystal Pharma Inc

NASDAQ COCP

Data sourced from iex and EODHD
Download Data

Cocrystal Pharma Inc Non-current Assets to Total Assets Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: 386.07%

Cocrystal Pharma Inc Non-current Assets to Total Assets Ratio 1 year YoY Change (%) is 386.07% for the Trailing 12 Months (TTM) ending March 31, 2024, a 512.57% change year over year. The non-current assets to total assets ratio measures the proportion of a company's non-current assets to its total assets. It is calculated by dividing the total non-current assets by the total assets. This ratio provides insights into the composition of a company's asset base and the extent to which it relies on non-current assets, such as property, plant, and equipment, to generate revenue. A higher ratio suggests a greater proportion of non-current assets, indicating potential long-term stability and investment in fixed assets. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Cocrystal Pharma Inc Non-current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.02, a -93.58% change year over year.
  • Cocrystal Pharma Inc Non-current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.25, a -39.26% change year over year.
  • Cocrystal Pharma Inc Non-current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.41, a -45.10% change year over year.
  • Cocrystal Pharma Inc Non-current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.74, a -22.12% change year over year.
NASDAQ: COCP

Cocrystal Pharma Inc

CEO Dr. Roger D. Kornberg Ph.D.
IPO Date May 19, 2011
Location United States
Headquarters 19805 North Creek Parkway, Bothell, WA, United States, 98011
Employees 12
Sector Healthcare
Industry Biotechnology
Description

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Similar companies

TPST

Tempest Therapeutics Inc

NA

NA

PULM

Pulmatrix Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email